MCID: PLS009
MIFTS: 64

Plasma Cell Neoplasm

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Plasma Cell Neoplasm

MalaCards integrated aliases for Plasma Cell Neoplasm:

Name: Plasma Cell Neoplasm 12 29 15 17 70
Plasma Cell Dyscrasia 12 6 70
Paraproteinemias 44 70
Plasma Cell Tumour 12
Plasmacytic Tumor 12
Multiple Myeloma 70
Plasmacytoma 70

Classifications:



External Ids:

Disease Ontology 12 DOID:6536
MeSH 44 D010265
SNOMED-CT 67 71390001
UMLS 70 C0026764 C0030489 C0032131 more

Summaries for Plasma Cell Neoplasm

Disease Ontology : 12 A mature B-cell neoplasm that is composed of plasma cells.

MalaCards based summary : Plasma Cell Neoplasm, also known as plasma cell dyscrasia, is related to plasma cell leukemia and myeloma, multiple. An important gene associated with Plasma Cell Neoplasm is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Epirubicin and Phentolamine have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Plasma Cell Neoplasm

Diseases related to Plasma Cell Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 351)
# Related Disease Score Top Affiliating Genes
1 plasma cell leukemia 32.5 NRAS KRAS FGFR3
2 myeloma, multiple 31.9 TP53 TET2 TCF3 NRAS MYD88 LIG4
3 myelofibrosis 31.1 TP53 TET2 HRAS FLT3 DNMT3A
4 myeloproliferative neoplasm 31.0 TET2 NRAS HRAS FLT3 FGFR3 DNMT3A
5 monoclonal gammopathy of uncertain significance 31.0 TP53 MYD88 FGFR3 DIS3 B2M
6 systemic mastocytosis 30.9 TET2 NRAS DNMT3A
7 sarcoma 30.7 TP53 NRAS KRAS HRAS FGFR3 CDK4
8 renal cell carcinoma, nonpapillary 30.7 TP53 NRAS HRAS FLT3 B2M ATM
9 leukemia, chronic myeloid 30.7 TP53 NRAS KRAS HRAS FLT3
10 glioblastoma 30.5 TP53 NRAS HRAS DNMT3A CDK4 ATM
11 lymphoma 30.5 TP53 MYD88 CDKN2C CDK4 B2M ATM
12 leukemia, chronic lymphocytic 30.5 TP53 NRAS MYD88 KRAS HRAS FLT3
13 carcinosarcoma 30.5 TP53 KRAS HRAS
14 lymphoma, non-hodgkin, familial 30.5 TP53 NRAS MYD88 FLT3 CDKN2C B2M
15 acute leukemia 30.4 TCF3 KRAS FLT3 DNMT3A
16 mantle cell lymphoma 30.4 TP53 CDK4 B2M ATM
17 diffuse large b-cell lymphoma 30.4 TP53 MYD88 CDK4 B2M
18 leukemia, acute myeloid 30.4 TP53 TET2 TCF3 NRAS KRAS IL7R
19 skin disease 30.4 TP53 NRAS HRAS FGFR3 B2M
20 myelodysplastic syndrome 30.3 TP53 TET2 NRAS KRAS HRAS FLT3
21 refractory plasma cell neoplasm 11.3
22 light chain deposition disease 11.2
23 waldenstroem's macroglobulinemia 11.2
24 poems syndrome 11.1
25 indolent plasma cell myeloma 11.1
26 polyneuropathy 10.8
27 hepatic flexure cancer 10.6 KRAS HRAS
28 pancreatic signet ring cell adenocarcinoma 10.6 TP53 KRAS HRAS
29 trachea carcinoma in situ 10.6 KRAS HRAS
30 signet ring cell adenocarcinoma 10.6 TP53 KRAS HRAS
31 signet ring basal cell carcinoma 10.6 KRAS HRAS
32 cobblestone retinal degeneration 10.6 KRAS HRAS
33 bone giant cell sarcoma 10.6 TP53 KRAS HRAS
34 ring chromosome 7 10.6 TP53 CDK4
35 biliary tract benign neoplasm 10.6 TP53 KRAS HRAS
36 malignant exocrine pancreas neoplasm 10.6 TP53 KRAS HRAS
37 immature teratoma of ovary 10.6 KRAS HRAS
38 acneiform dermatitis 10.6 NRAS KRAS HRAS
39 appendix disease 10.6 TP53 KRAS HRAS
40 papillary adenoma 10.6 TP53 KRAS HRAS
41 actinic cheilitis 10.6 TP53 FGFR3
42 appendix cancer 10.6 TP53 KRAS HRAS
43 epidermolytic nevus 10.6 NRAS FGFR3
44 nasal cavity adenocarcinoma 10.6 TP53 KRAS HRAS
45 female reproductive endometrioid cancer 10.6 TP53 KRAS HRAS
46 anus cancer 10.6 TP53 KRAS HRAS
47 mediastinum liposarcoma 10.6 CDK4 ATM
48 duodenum cancer 10.6 TP53 KRAS HRAS
49 oculoectodermal syndrome 10.6 NRAS KRAS HRAS
50 testicular spermatocytic seminoma 10.6 HRAS FGFR3 DNMT3A

Comorbidity relations with Plasma Cell Neoplasm via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Bronchitis
Chronic Kidney Disease Deficiency Anemia
Heart Disease Monoclonal Paraproteinemia
Neutropenia Osteoporosis

Graphical network of the top 20 diseases related to Plasma Cell Neoplasm:



Diseases related to Plasma Cell Neoplasm

Symptoms & Phenotypes for Plasma Cell Neoplasm

GenomeRNAi Phenotypes related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

26 (show all 18)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.69 AURKA HRAS KRAS
2 Decreased viability GR00055-A-2 10.69 AURKA HRAS KRAS
3 Decreased viability GR00055-A-3 10.69 KRAS
4 Decreased viability GR00106-A-0 10.69 KRAS
5 Decreased viability GR00173-A 10.69 FLT3
6 Decreased viability GR00221-A-1 10.69 AURKA CYLD FGFR3 HRAS KRAS CDKN2C
7 Decreased viability GR00221-A-2 10.69 AURKA CYLD FGFR3 HRAS KRAS
8 Decreased viability GR00221-A-3 10.69 FGFR3 HRAS NRAS
9 Decreased viability GR00221-A-4 10.69 AURKA FLT3
10 Decreased viability GR00231-A 10.69 AURKA
11 Decreased viability GR00249-S 10.69 AURKA CYLD FGFR3 CDKN2C
12 Decreased viability GR00301-A 10.69 CYLD KRAS CDKN2C
13 Decreased viability GR00381-A-1 10.69 KRAS
14 Decreased viability GR00402-S-2 10.69 AURKA CYLD
15 Decreased cell migration GR00055-A-1 9.65 ATM CDK4 FGFR3
16 Decreased cell migration GR00055-A-3 9.65 AURKA HRAS
17 Reduced mammosphere formation GR00396-S 9.23 ATM CDK4 DNMT3A HRAS KRAS MYD88
18 Increased senescence-associated beta-galactosidase protein expression after pRB stimulation GR00230-A-2 8.65 FLT3

MGI Mouse Phenotypes related to Plasma Cell Neoplasm:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.51 ATM AURKA B2M CDK4 CDKN2C CYLD
2 growth/size/body region MP:0005378 10.5 ATM AURKA B2M CDK4 CDKN2C CRBN
3 hematopoietic system MP:0005397 10.47 ATM B2M CDK4 CDKN2C CRBN CYLD
4 endocrine/exocrine gland MP:0005379 10.46 ATM B2M CDK4 CDKN2C CYLD DNMT3A
5 behavior/neurological MP:0005386 10.44 ATM CDK4 CDKN2C CRBN CYLD DIS3
6 homeostasis/metabolism MP:0005376 10.43 ATM B2M CDK4 CDKN2C CRBN CYLD
7 immune system MP:0005387 10.41 ATM B2M CDK4 CDKN2C CRBN CYLD
8 mortality/aging MP:0010768 10.41 ATM AURKA B2M CDK4 CDKN2C CRBN
9 cardiovascular system MP:0005385 10.37 ATM AURKA B2M CDK4 CDKN2C CRBN
10 neoplasm MP:0002006 10.33 ATM AURKA B2M CDK4 CDKN2C CYLD
11 digestive/alimentary MP:0005381 10.32 B2M CDK4 CRBN CYLD FGFR3 HRAS
12 embryo MP:0005380 10.22 ATM AURKA B2M CDK4 DNMT3A KRAS
13 nervous system MP:0003631 10.21 ATM AURKA B2M CDK4 CDKN2C CRBN
14 integument MP:0010771 10.19 ATM B2M CDK4 CDKN2C CYLD FGFR3
15 liver/biliary system MP:0005370 10.16 B2M CDK4 CRBN KRAS LIG4 MYD88
16 limbs/digits/tail MP:0005371 10.02 AURKA CYLD FGFR3 KRAS NRAS TCF3
17 no phenotypic analysis MP:0003012 10.02 AURKA FGFR3 FLT3 HRAS KRAS MYD88
18 normal MP:0002873 9.96 CDK4 CYLD FGFR3 HRAS IL7R KRAS
19 renal/urinary system MP:0005367 9.81 CDK4 CDKN2C FGFR3 HRAS KRAS MYD88
20 reproductive system MP:0005389 9.7 ATM B2M CDK4 CDKN2C DNMT3A FGFR3
21 vision/eye MP:0005391 9.28 AURKA CDK4 CRBN DIS3 FGFR3 KRAS

Drugs & Therapeutics for Plasma Cell Neoplasm

Drugs for Plasma Cell Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 589)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 4 56420-45-2 41867
2
Phentolamine Approved Phase 4 50-60-2 5775
3
Ofloxacin Approved Phase 4 82419-36-1 4583
4
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
5
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
6
Pirarubicin Investigational Phase 4 72496-41-4
7 Epoetin alfa Phase 4 113427-24-0
8 Hematinics Phase 4
9
Apixaban Approved Phase 3 503612-47-3 10182969
10
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
11
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
12
Pamidronate Approved Phase 3 40391-99-9 4674
13
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
14
Denosumab Approved Phase 3 615258-40-7
15
Carvedilol Approved, Investigational Phase 3 72956-09-3 2585
16
Enalaprilat Approved Phase 3 76420-72-9 6917719
17
Enalapril Approved, Vet_approved Phase 3 75847-73-3 5362032 40466924
18
Idarubicin Approved Phase 3 58957-92-9 42890
19
Amifostine Approved, Investigational Phase 3 20537-88-6 2141
20
Ifosfamide Approved Phase 3 3778-73-2 3690
21
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
22
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
23
deoxycholic acid Approved Phase 3 83-44-3 222528
24
Iron Approved Phase 3 7439-89-6 23925 29936
25
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
26
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
27
Tazobactam Approved Phase 3 89786-04-9 123630
28
Vancomycin Approved Phase 3 1404-90-6 14969 441141
29
Piperacillin Approved Phase 3 66258-76-2 43672
30
Amitriptyline Approved Phase 3 50-48-6 2160
31
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
32
Baclofen Approved Phase 3 1134-47-0 2284
33
Perphenazine Approved Phase 3 58-39-9 4748
34
Rivaroxaban Approved Phase 2, Phase 3 366789-02-8
35
Hydrocodone Approved, Illicit, Investigational Phase 3 125-29-1 5284569
36
Ketorolac Approved Phase 3 74103-06-3, 66635-83-4 3826
37
Mycophenolic acid Approved Phase 3 24280-93-1 446541
38
tannic acid Approved Phase 3 1401-55-4
39
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
40
Acetaminophen Approved Phase 3 103-90-2 1983
41
Tacrolimus Approved, Investigational Phase 3 104987-11-3 6473866 445643 439492
42
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
43
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
44
Promethazine Approved, Investigational Phase 3 60-87-7 4927
45
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
46
Ranitidine Approved, Withdrawn Phase 3 66357-35-5, 66357-59-3, 82530-72-1 3001055
47
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
48
Venetoclax Approved, Investigational Phase 3 1257044-40-8 49846579
49
Thalidomide Approved, Investigational, Withdrawn Phase 3 50-35-1 5426
50
Dalteparin Approved Phase 3 9005-49-6

Interventional clinical trials:

(show top 50) (show all 2730)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Double Arms, Prospective Phase 4 Study to Evaluating the Efficacy and Safety of Combination Therapy of PAD Versus VCD Treatment in Previously Untreated Subjects With Multiple Myeloma. Unknown status NCT01868828 Phase 4 PAD;VCD
2 Study of Efficacy of PAD-regimen(Bortezomib,Pirarubicin and Dexamethasone) and TAD-regimen(Thalidomide,Pirarubicin and Dexamethasone) in Newly Diagnosed Multiple Myeloma,Influence in Concentration of Bone Metabolites,and the Relations With Different Cytogenetic and Molecular Biological Changes Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
3 An Open-Label Phase IV Study of the Efficacy of Bortezomib-based Combination Therapy the Treatment of Subjects With Multiple Myeloma Unknown status NCT02559154 Phase 4 Bortezomib;Dexamethasone;Doxorubicin;Cyclophosphamide;Mitoxsnteone;Thalidomide
4 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
5 A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
6 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy Completed NCT02958969 Phase 4 Apixaban
7 A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone;Melphalan;G-CSF;Cyclophosphamide;Mesna
8 A Multicenter,Open Label, Randomized Trial Evaluating the Duration of Infusion of Zoledronic Acid 4 mg IV in Multiple Myeloma Patients With Bone Metastases Completed NCT00104104 Phase 4 zoledronic acid
9 Assessment of the Antitumour Effect of Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse: Prospective Clinical Trial of the GEM/PETHEMA Group Completed NCT01087008 Phase 4 zoledronic acid
10 Evaluation of VELCADE (Botezomib) for Injection Employed as Re-Treatment for Efficacy, Safety, and Tolerability Completed NCT00257114 Phase 4 bortezomib
11 Pharmacokinetic Study of Bortezomib (VELCADE) Administered Intravenously in Taiwanese Patients With Multiple Myeloma - A Post Approval Commitment Study Completed NCT02268890 Phase 4 Bortezomib
12 Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Advanced Multiple Myeloma Completed NCT00622505 Phase 4 zoledronic acid
13 Thalidomide-Cyclophosphamide-Dexamethasone in Patients < 75 Years or Velcade-Melfalan-Prednisone (V-MP)/Thalidomide-Cyclophosphamide-Dexamethasone in Patients >75 Years, in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4 Bortezomib;Thalidomide;Bortezomib
14 An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
15 A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety Completed NCT00434447 Phase 4 Zoledronic acid
16 The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia Completed NCT00524407 Phase 4 Epoetin alfa
17 An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures Completed NCT00211211 Phase 4
18 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
19 RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma Recruiting NCT03908138 Phase 4 RDD;VDD
20 Influenza Vaccination in Plasma Cell Dyscrasias Recruiting NCT04080531 Phase 4
21 Post-marketing Phase 4 Study to Evaluate Safety, Tolerability, and Efficacy of Kyprolis® (Carfilzomib) in Indian Patients With Relapsed or Refractory Multiple Myeloma: A Prospective, Open-label, Non-comparative, Multicenter Study Recruiting NCT03934684 Phase 4 Drug: Carfilzomib + Dexamethasone;Drug: Carfilzomib + Lenalidomide + Dexamethasone
22 Magnolia Study Prolonged Protection From Bone Disease in Multiple Myeloma. An Open Label Phase 3 Multicenter International Randomised Trial Recruiting NCT02286830 Phase 4 Zoledronic acid
23 An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6) Recruiting NCT03173092 Phase 4 Ixazomib;Lenalidomide;Dexamethasone
24 A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) INELIGIBLE COMMUNITY POPULATION AFFECTED BY MULTIPLE MYELOMA (MM) Recruiting NCT03829371 Phase 4 Velcade;Melphalan;Prednisone;Lenalidomide;Dexamethasone
25 A Prospective, Single-Arm, Multicenter, Pragmatic Phase-IV Trial Investigating Safety and Effectiveness of DARZALEX (Daratumumab) In Indian Subjects With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent Recruiting NCT03768960 Phase 4 Daratumumab
26 Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients Recruiting NCT04348006 Phase 4 Bortezomib 3.5 MG
27 A Multicenter, Open-label, Prospective Study of Ixazomib, Lenalidomide, and Ixazomib in Combination With Lenalidomide for Maintenance Therapy in Patients With Newly Diagnosed Multiple Myeloma Recruiting NCT04217967 Phase 4 Ixazomib;Lenalidomide
28 An Open-label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Active, not recruiting NCT03416374 Phase 4 Ixazomib;Bortezomib;Carfilzomib;Lenalidomide;Dexamethasone
29 Doxorubicin Hydrochloride Liposome vs Doxorubicin Combined With Bortizomib and Dexamethasone to Treat Initially Diagnosed Multiple Myeloma: A Randomized Prospective Clinical Study Active, not recruiting NCT02577783 Phase 4 PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone;PAD regimen: bortizomib, dexamethasone and doxorubicin
30 Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Enrolling by invitation NCT03619252 Phase 4 Standard Antibacterial Prophylaxis
31 Clinical, Multicenter, Single-arm, Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma (MM) Newly Diagnosed Symptomatic ≥75 Years Terminated NCT02773550 Phase 4 Bortezomib;Melphalan;Prednisone
32 Randomised Controlled Open-label Study to Evaluate Efficacy & Safety of Intravenous Ferric Carboxymaltose Versus no Treatment in Anaemic Subjects With Multiple Myeloma & Iron Restricted Erythropoiesis Receiving Chemotherapy Terminated NCT01100879 Phase 4 Ferric carboxymaltose
33 Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment Terminated NCT02608060 Phase 4 Epoetin Beta
34 Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma Withdrawn NCT01410929 Phase 4
35 Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. Withdrawn NCT00242528 Phase 4 Zoledronic acid
36 Reduction of Antigen-Lipid-Driven Monoclonal Gammopathies by Targeting Epicardial Fat and Its Lipids Content With Liraglutide: A Glucagon Like Peptide-1 Receptor Analogue (GLP-1RA) Withdrawn NCT02920190 Phase 4 Liraglutide
37 A Phase 3 Trial Comparing Cyclophosphamide,Bortezomib,and Dexamethasone (CyBorD) and Bortezomib,Doxorubicin,and Dexamethasone (PAD) in the Treatment of Newly Diagnosed Multiple Myeloma Unknown status NCT02362165 Phase 3 Cyclophosphamide;Bortezomib;Dexamethasone;Doxorubicin
38 Clarithromycin Plus CTd (Cyclophosphamide,Thalidomide and Dexamethasone)Regimen for Patients With Newly Diagnosed Multiple Myeloma:a Phase 3 , Multicenter,Randomized, Open-Label Trial. Unknown status NCT02248428 Phase 3 Clarithromycin;Thalidomide;Cyclophosphamide;Dexamethasone
39 A Phase 3 Study of Velcade (Bortezomib) Dexamethasone (VD) Versus Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) as an Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma Unknown status NCT00910897 Phase 3 Velcade-Dexamethasone;Velcade-Thalidomide-Dexamethasone
40 Iberoamerican Phase III International Study, Open, Multicenter, Randomized, Comparative of Thalidomide / Cyclophosphamide / Dexamethasone Versus Thalidomide / Dexamethasone Versus Thalidomide / Melphalan / Prednisone as Induction Therapy Followed by Maintenance Therapy With Thalidomide + Prednisone Versus Thalidomide Alone in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65years. Unknown status NCT01532856 Phase 3 Thalidomide, Cyclophosphamide, Dexamethasone;Thalidomide, Dexamethasone;Thalidomide, Melphalan, Prednisone
41 A Randomized, Phase III, Placebo-Controlled Multicenter Study to Demonstrate the Effectiveness and Safety of the Combination Enzyme Tablet (Wobe-Mugos E) as Adjuvant Therapy to Standard of Care Treatment in Patients With Stages II or III Multiple Myeloma Unknown status NCT00014339 Phase 3 Wobe-Mugos E;melphalan;prednisone
42 A Randomized Phase III Study On The Effect Of Thalidomide Combined With Adriamycin, Dexamethasone (AD) And High Dose Melphalan In Patients With Multiple Myeloma Unknown status NCT00028886 Phase 3 cyclophosphamide;dexamethasone;doxorubicin hydrochloride;melphalan;thalidomide;vincristine sulfate
43 VIIITH MYELOMATOSIS TRIAL: A RANDOMISED TRIAL OF TREATMENT FOR INDUCING FIRST PLATEAU PHASE ABCM VS 3 COURSES OF ABCM FOLLOWED BY ORAL WEEKLY CYCLOPHOSPHAMIDE Unknown status NCT00002653 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;prednisone
44 A Randomised Study Comparing CIDEX (CCNU, Oral Idarubicin and Dexamethasone) With Melphalan and Prednisolone in Relapsed Multiple Myeloma Unknown status NCT00003603 Phase 3 cyclophosphamide;dexamethasone;idarubicin;lomustine;melphalan;prednisolone
45 MYELOMA VII MEDICAL RESEARCH COUNCIL WORKING PARTY ON LEUKEMIA IN ADULTS: MYELOMATOSIS THERAPY TRIAL Unknown status NCT00002599 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;methylprednisolone;prednisone;vincristine sulfate
46 Myeloma X Relapse (Intensive): A Phase III Study to Determine the Role of a Second Autologous Stem Cell Transplant as Consolidation Therapy in Patients With Relapsed Multiple Myeloma Following Prior High-dose Chemotherapy and Autologous Stem Cell Rescue. Unknown status NCT00747877 Phase 3 cyclophosphamide;melphalan
47 Comparable Investigation of One Fraction Radiotherapy (8 Gy x 1) and Multifraction Radiotherapy (3 Gy x 10) of Painful Bone Destructions in Patients With Multiple Myeloma. Unknown status NCT02024815 Phase 3
48 Study of Cyclophosphamide,Liposome Doxorubicin Dexamethasone(CDD) Plus Bortezomib Compared With CDD in the Relapsed or Refractory Multiple Myeloma Combined With Extramedullary Plasmacytoma Patients Unknown status NCT02336386 Phase 3 CDD;CDD Plus Bortezomib
49 Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia Unknown status NCT00482716 Phase 3
50 A Phase 3, Prospective, Randomized Clinical Study of VELCADE-Thalidomide-Dexamethasone (VTD) Versus Thalidomide-Dexamethasone (TD) for Previously Untreated Multiple Myeloma (MM) Patients Who Are Candidates to Receive Double Autologous Transplantation Unknown status NCT01134484 Phase 3 Velcade;Thalidomide;Dexamethasone

Search NIH Clinical Center for Plasma Cell Neoplasm

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Aldesleukin
bortezomib
carfilzomib
Carmustine
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
Melphalan
Melphalan hydrochloride
panobinostat
peginterferon alfa-2a
peginterferon alfa-2b
Procarbazine
Procarbazine Hydrochloride
Recombinant interferon beta-1a
Recombinant interferon beta-1b
Thalidomide
ZOLEDRONIC
zoledronic acid

Cochrane evidence based reviews: paraproteinemias

Genetic Tests for Plasma Cell Neoplasm

Genetic tests related to Plasma Cell Neoplasm:

# Genetic test Affiliating Genes
1 Plasma Cell Neoplasm 29

Anatomical Context for Plasma Cell Neoplasm

MalaCards organs/tissues related to Plasma Cell Neoplasm:

40
Bone, T Cells, Bone Marrow, Myeloid, Kidney, Skin, Nk Cells

Publications for Plasma Cell Neoplasm

Articles related to Plasma Cell Neoplasm:

(show top 50) (show all 1388)
# Title Authors PMID Year
1
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 6
26619011 2016
2
Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. 6
19855393 2009
3
An epidermal nevus syndrome with cerebral involvement caused by a mosaic FGFR3 mutation. 6
18642369 2008
4
Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. 6
16841094 2006
5
Thanatophoric dysplasia type 2 with encephalocele during the second trimester. 6
16752380 2006
6
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. 6
15772091 2005
7
Somatic and germline mosaicism for a R248C missense mutation in FGFR3, resulting in a skeletal dysplasia distinct from thanatophoric dysplasia. 6
12833394 2003
8
The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum. 6
12624096 2003
9
Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). 6
11529856 2001
10
Prenatal diagnosis of thanatophoric dysplasia by mutational analysis of the fibroblast growth factor receptor 3 gene and a proposed correction of previously published PCR results. 6
10073901 1999
11
Molecular, radiologic, and histopathologic correlations in thanatophoric dysplasia. 6
9677066 1998
12
Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. 6
9207791 1997
13
Japanese cases of type 1 thanatophoric dysplasia exclusively carry a C to T transition at nucleotide 742 of the fibroblast growth factor receptor 3 gene. 6
8858131 1996
14
Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. 6
7773297 1995
15
Association between anthropometry and lifestyle factors and risk of B-cell lymphoma: An exposome-wide analysis. 61
33128820 2021
16
Masson Trichrome and Sulfated Alcian Blue Stains Distinguish Light Chain Deposition Disease From Amyloidosis in the Lung. 61
33002919 2021
17
Survival patterns among venous thromboembolism patients with hematologic malignancies in Alberta, Canada from 2003 to 2015. 61
33429125 2021
18
Immunological Prognostic Factors in Multiple Myeloma. 61
33808304 2021
19
Extramedullary relapse of multiple myeloma presenting as a breast lump. 61
33687938 2021
20
Comparing neuropathy in multiple myeloma and AL amyloidosis. 61
33368817 2021
21
Hypercalcaemia, renal failure, anaemia and osteolytic lesions (CRAB) in chronic lymphocytic leukaemia mimicking multiple myeloma. 61
33653837 2021
22
"Transient plasma cell dyscrasia in COVID-19 patients linked to IL-6 triggering." 61
33753206 2021
23
Neuropathy associated with IgA monoclonal Gammopathy. A harbinger of AL amyloidosis. 61
33578240 2021
24
Revealing serum lipidomic characteristics and potential lipid biomarkers in patients with POEMS syndrome. 61
33779058 2021
25
Pyoderma gangrenosum with plasma cell dyscrasia should be subject for anti-myeloma treatment. 61
33751551 2021
26
Recalcitrant cutaneous pyoderma gangrenosum with pulmonary involvement resolved with treatment of underlying plasma cell dyscrasia. 61
33604440 2021
27
Quantitative and qualitative assessment of plasma cell dyscrasias in dual-layer spectral CT. 61
33783572 2021
28
Coexistence of amyloidosis and light chain deposition disease in the heart. 61
33264681 2021
29
Left ventricular systolic dysfunction with concomitant bradyarrhythmia in a patient with POEMS syndrome: a case report. 61
33598607 2021
30
A Case Report of Acquired Factor X Deficiency in a Patient With Multiple Myeloma. 61
33728224 2021
31
Pulmonary arterial hypertension in a patient with multiple myeloma during carfilzomib treatment: in search of better management. 61
33525991 2021
32
Myeloma of Laryngeal Cartilage: Literature Review and Case Study. 61
31284752 2021
33
Pulmonary Vascular Disease Due to Plasma Cell Dyscrasia. 61
33718795 2021
34
Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma. 61
33579893 2021
35
AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival. 61
33347707 2021
36
Plasma cell neoplasms of the bladder: a series of 9 cases. 61
33639141 2021
37
A pharmacist's review of the treatment of systemic light chain amyloidosis. 61
33028132 2021
38
Fine-Needle Aspiration Cytology in Preoperative Diagnosis of Bone Lesions: A Three-Year Study in a Tertiary Care Hospital. 61
33181515 2021
39
The Value of Cellblock in Diagnosing Pancreatic Lymphomas. 61
32854095 2021
40
What Is New in the Treatment of Smoldering Multiple Myeloma? 61
33499196 2021
41
Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma. 61
33445467 2021
42
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma. 61
32079692 2021
43
An atypical chronic neutrophilic leukemia patient harboring ASXL1 and NRAS mutations associated with monoclonal plasma cell dyscrasia presenting as hemopericardium. 61
32052135 2021
44
Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies. 61
33388856 2021
45
Combined Schwannoma and Kappa-Restricted Plasma Cell Neoplasm: A Case Report and Review of the Literature. 61
33510923 2021
46
Spontaneous Splenic Artery Rupture as the First Symptom of Systemic Amyloidosis. 61
33763260 2021
47
Serum Hevylite® assay in the differential diagnosis of patients with high suspicion of AL Amyloidosis. 61
33455086 2021
48
The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study. 61
32846200 2020
49
Case report: Oral manifestations of systemic amyloidosis, an aid to diagnosis of multiple myeloma - report of two cases. 61
33408060 2020
50
A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact. 61
33275748 2020

Variations for Plasma Cell Neoplasm

ClinVar genetic disease variations for Plasma Cell Neoplasm:

6 (show top 50) (show all 196)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 FGFR3 NM_000142.5(FGFR3):c.1948A>G (p.Lys650Glu) SNV Pathogenic 16331 rs78311289 GRCh37: 4:1807889-1807889
GRCh38: 4:1806162-1806162
2 LIG4 NM_206937.2(LIG4):c.2440C>T (p.Arg814Ter) SNV Pathogenic 7673 rs104894419 GRCh37: 13:108861177-108861177
GRCh38: 13:108208829-108208829
3 KRAS NM_004985.5(KRAS):c.35G>C (p.Gly12Ala) SNV Pathogenic 45122 rs121913529 GRCh37: 12:25398284-25398284
GRCh38: 12:25245350-25245350
4 FGFR3 FGFR3, FGFR3/IGH FUSION Variation Pathogenic 16343 GRCh37:
GRCh38:
5 FGFR3 NM_000142.5(FGFR3):c.742C>T (p.Arg248Cys) SNV Pathogenic/Likely pathogenic 16332 rs121913482 GRCh37: 4:1803564-1803564
GRCh38: 4:1801837-1801837
6 HRAS , LRRC56 NM_005343.4(HRAS):c.37G>T (p.Gly13Cys) SNV Likely pathogenic 12606 rs104894228 GRCh37: 11:534286-534286
GRCh38: 11:534286-534286
7 PTPN11 NM_002834.4(PTPN11):c.226G>A (p.Glu76Lys) SNV Likely pathogenic 13336 rs121918464 GRCh37: 12:112888210-112888210
GRCh38: 12:112450406-112450406
8 BRAF NM_001374258.1(BRAF):c.1907G>T (p.Gly636Val) SNV Likely pathogenic 40387 rs397507483 GRCh37: 7:140453148-140453148
GRCh38: 7:140753348-140753348
9 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His) SNV Likely pathogenic 12366 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
10 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Likely pathogenic 12356 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
11 TP53 NM_000546.6(TP53):c.451C>T (p.Pro151Ser) SNV Likely pathogenic 12370 rs28934874 GRCh37: 17:7578479-7578479
GRCh38: 17:7675161-7675161
12 BRAF NM_001374258.1(BRAF):c.1919T>A (p.Val640Glu) SNV Likely pathogenic 13961 rs113488022 GRCh37: 7:140453136-140453136
GRCh38: 7:140753336-140753336
13 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp) SNV Likely pathogenic 12347 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
14 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg) SNV Likely pathogenic 13900 rs11554290 GRCh37: 1:115256529-115256529
GRCh38: 1:114713908-114713908
15 TP53 NM_000546.6(TP53):c.583A>T SNV Likely pathogenic 376617 rs942158624 GRCh37: 17:7578266-7578266
GRCh38: 17:7674948-7674948
16 HRAS , LRRC56 NM_005343.4(HRAS):c.34G>A (p.Gly12Ser) SNV Likely pathogenic 12602 rs104894229 GRCh37: 11:534289-534289
GRCh38: 11:534289-534289
17 BRAF NM_001374258.1(BRAF):c.1526G>A (p.Gly509Glu) SNV Likely pathogenic 13974 rs121913355 GRCh37: 7:140481402-140481402
GRCh38: 7:140781602-140781602
18 KMT2D NM_003482.3(KMT2D):c.12844C>T (p.Arg4282Ter) SNV Likely pathogenic 372805 rs1057517992 GRCh37: 12:49425644-49425644
GRCh38: 12:49031861-49031861
19 KRAS NM_004985.5(KRAS):c.182A>T (p.Gln61Leu) SNV Likely pathogenic 45116 rs121913240 GRCh37: 12:25380276-25380276
GRCh38: 12:25227342-25227342
20 NRAS NM_002524.5(NRAS):c.38G>T (p.Gly13Val) SNV Likely pathogenic 375876 rs121434596 GRCh37: 1:115258744-115258744
GRCh38: 1:114716123-114716123
21 NRAS NM_002524.5(NRAS):c.37G>C (p.Gly13Arg) SNV Likely pathogenic 13899 rs121434595 GRCh37: 1:115258745-115258745
GRCh38: 1:114716124-114716124
22 BRAF NM_001374258.1(BRAF):c.1910T>A (p.Leu637Gln) SNV Likely pathogenic 76687 rs121913366 GRCh37: 7:140453145-140453145
GRCh38: 7:140753345-140753345
23 FLT3 NM_004119.3(FLT3):c.1714T>C (p.Tyr572His) SNV Likely pathogenic 800354 rs1208575764 GRCh37: 13:28608342-28608342
GRCh38: 13:28034205-28034205
24 TP53 NM_000546.6(TP53):c.396G>C (p.Lys132Asn) SNV Likely pathogenic 376624 rs866775781 GRCh37: 17:7578534-7578534
GRCh38: 17:7675216-7675216
25 TP53 NM_000546.5(TP53):c.584T>A (p.Ile195Asn) SNV Likely pathogenic 376618 rs760043106 GRCh37: 17:7578265-7578265
GRCh38: 17:7674947-7674947
26 BRAF NM_001374258.1(BRAF):c.1901A>G (p.Asp634Gly) SNV Likely pathogenic 13972 rs121913338 GRCh37: 7:140453154-140453154
GRCh38: 7:140753354-140753354
27 NRAS NM_002524.5(NRAS):c.35G>C (p.Gly12Ala) SNV Likely pathogenic 219097 rs121913237 GRCh37: 1:115258747-115258747
GRCh38: 1:114716126-114716126
28 TP53 NM_000546.5(TP53):c.815T>A (p.Val272Glu) SNV Likely pathogenic 376673 rs876660333 GRCh37: 17:7577123-7577123
GRCh38: 17:7673805-7673805
29 TP53 NM_000546.5(TP53):c.585C>G (p.Ile195Met) SNV Likely pathogenic 376620 rs1057519994 GRCh37: 17:7578264-7578264
GRCh38: 17:7674946-7674946
30 TP53 NM_000546.5(TP53):c.832C>G (p.Pro278Ala) SNV Likely pathogenic 376645 rs17849781 GRCh37: 17:7577106-7577106
GRCh38: 17:7673788-7673788
31 TP53 NM_001126115.1(TP53):c.-3A>C SNV Likely pathogenic 376628 rs747342068 GRCh37: 17:7578536-7578536
GRCh38: 17:7675218-7675218
32 TP53 NM_000546.5(TP53):c.832C>T (p.Pro278Ser) SNV Likely pathogenic 376642 rs17849781 GRCh37: 17:7577106-7577106
GRCh38: 17:7673788-7673788
33 TP53 NM_000546.5(TP53):c.833C>T (p.Pro278Leu) SNV Likely pathogenic 232497 rs876659802 GRCh37: 17:7577105-7577105
GRCh38: 17:7673787-7673787
34 FAT1 NM_005245.4(FAT1):c.2668G>A (p.Glu890Lys) SNV Likely pathogenic 800309 rs1579484570 GRCh37: 4:187628314-187628314
GRCh38: 4:186707160-186707160
35 CREBBP NM_004380.3(CREBBP):c.5188A>G (p.Ile1730Val) SNV Likely pathogenic 800310 rs1159294530 GRCh37: 16:3779860-3779860
GRCh38: 16:3729859-3729859
36 RXRA NM_002957.6(RXRA):c.671G>A (p.Ser224Asn) SNV Likely pathogenic 800311 rs1588299621 GRCh37: 9:137309064-137309064
GRCh38: 9:134417218-134417218
37 TCF3 NM_003200.5(TCF3):c.1823-478G>A SNV Likely pathogenic 800312 rs1599413207 GRCh37: 19:1612326-1612326
GRCh38: 19:1612327-1612327
38 NKX2-1 , SFTA3 NM_001079668.3(NKX2-1):c.436G>A (p.Ala146Thr) SNV Likely pathogenic 800313 rs1594406727 GRCh37: 14:36988217-36988217
GRCh38: 14:36519012-36519012
39 TET3 NM_001287491.2(TET3):c.2362G>A (p.Glu788Lys) SNV Likely pathogenic 800314 rs751524927 GRCh37: 2:74275406-74275406
GRCh38: 2:74048279-74048279
40 KMT2C NM_170606.3(KMT2C):c.9181C>G (p.Gln3061Glu) SNV Likely pathogenic 800315 rs1587941402 GRCh37: 7:151873357-151873357
GRCh38: 7:152176272-152176272
41 TRAF5 NM_001033910.3(TRAF5):c.1250_1251AG[2] (p.Glu419fs) Microsatellite Likely pathogenic 800316 rs756183569 GRCh37: 1:211545620-211545623
GRCh38: 1:211372278-211372281
42 H2AC17 NM_003514.2(H2AC17):c.364G>A (p.Glu122Lys) SNV Likely pathogenic 800317 rs1581495906 GRCh37: 6:27860564-27860564
GRCh38: 6:27892786-27892786
43 KDM5C NM_004187.5(KDM5C):c.67G>T (p.Glu23Ter) SNV Likely pathogenic 800318 rs1602247047 GRCh37: X:53254005-53254005
GRCh38: X:53224823-53224823
44 HDAC4 NM_006037.3(HDAC4):c.1565C>T (p.Pro522Leu) SNV Likely pathogenic 800319 rs372078034 GRCh37: 2:240036960-240036960
GRCh38: 2:239115264-239115264
45 CRBN , TRNT1 NM_001367321.1(TRNT1):c.*1998T>A SNV Likely pathogenic 800320 rs1575079076 GRCh37: 3:3194188-3194188
GRCh38: 3:3152504-3152504
46 MST1R NM_002447.4(MST1R):c.1477G>T (p.Asp493Tyr) SNV Likely pathogenic 800321 rs1575446356 GRCh37: 3:49936371-49936371
GRCh38: 3:49898938-49898938
47 PIK3R2 NM_005027.4(PIK3R2):c.572C>A (p.Ser191Ter) SNV Likely pathogenic 800322 rs1418268495 GRCh37: 19:18271969-18271969
GRCh38: 19:18161159-18161159
48 BAP1 NM_004656.4(BAP1):c.1787G>C (p.Ser596Thr) SNV Likely pathogenic 800323 rs1478603808 GRCh37: 3:52437257-52437257
GRCh38: 3:52403241-52403241
49 H2AC16 NM_003511.3(H2AC16):c.44C>G (p.Ala15Gly) SNV Likely pathogenic 800324 rs890521687 GRCh37: 6:27833176-27833176
GRCh38: 6:27865398-27865398
50 NCOR2 NM_006312.6(NCOR2):c.5909C>A (p.Ser1970Tyr) SNV Likely pathogenic 800325 rs1593107841 GRCh37: 12:124821505-124821505
GRCh38: 12:124336959-124336959

Copy number variations for Plasma Cell Neoplasm from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 17396 1 142600000 155000000 Gain Plasma-cell dyscrasia

Expression for Plasma Cell Neoplasm

Search GEO for disease gene expression data for Plasma Cell Neoplasm.

Pathways for Plasma Cell Neoplasm

Pathways related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.76 TP53 TCF3 NRAS KRAS IL7R HRAS
2
Show member pathways
13.59 TP53 TCF3 NRAS KRAS IL7R HRAS
3
Show member pathways
13.46 TP53 NRAS MYD88 KRAS IL7R HRAS
4
Show member pathways
13.37 TP53 NRAS MYD88 KRAS IL7R HRAS
5
Show member pathways
13.25 TP53 NRAS MYD88 KRAS HRAS CYLD
6
Show member pathways
12.93 TP53 NRAS KRAS HRAS FLT3 CDK4
7
Show member pathways
12.88 TP53 NRAS MYD88 KRAS HRAS CDK4
8
Show member pathways
12.81 TP53 NRAS KRAS HRAS CDK4
9
Show member pathways
12.81 TP53 NRAS KRAS IL7R HRAS FLT3
10
Show member pathways
12.79 NRAS KRAS HRAS FLT3 FGFR3
11
Show member pathways
12.77 TP53 NRAS KRAS HRAS FGFR3
12
Show member pathways
12.76 TP53 NRAS MYD88 KRAS HRAS ATM
13 12.76 TP53 NRAS KRAS IL7R HRAS FLT3
14 12.75 TP53 NRAS MYD88 KRAS HRAS FLT3
15
Show member pathways
12.68 TP53 NRAS KRAS HRAS FGFR3
16
Show member pathways
12.66 NRAS MYD88 KRAS HRAS CDK4
17
Show member pathways
12.64 TP53 NRAS KRAS HRAS CDKN2C CDK4
18
Show member pathways
12.57 TP53 NRAS KRAS HRAS FGFR3
19
Show member pathways
12.56 TP53 NRAS KRAS HRAS FGFR3
20 12.52 TP53 LIG4 CDKN2C CDK4 AURKA ATM
21
Show member pathways
12.46 TP53 NRAS KRAS HRAS FGFR3 ATM
22
Show member pathways
12.45 NRAS KRAS HRAS FLT3 FGFR3
23
Show member pathways
12.45 NRAS KRAS HRAS FLT3 FGFR3
24 12.44 TP53 NRAS KRAS HRAS FGFR3 DNMT3A
25 12.41 TP53 CDKN2C CDK4 ATM
26
Show member pathways
12.4 TP53 CDKN2C CDK4 ATM
27
Show member pathways
12.38 NRAS KRAS HRAS FLT3
28 12.35 TP53 NRAS KRAS HRAS
29
Show member pathways